TBIO Quote, Financials, Valuation and Earnings

Intelligent Bio Solutions has a net margin of -811.94% compared to Telesis Bio's net margin of -307.88%. Telesis Bio's return on equity of -151.32% beat Intelligent Bio Solutions's return on equity of -176.44%.

Telesis Bio has a consensus price target of --, signalling upside risk potential of 16171.17%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 733.28%. Given that Telesis Bio has higher upside potential than Intelligent Bio Solutions, analysts believe Telesis Bio is more attractive than Intelligent Bio Solutions.

Telesis Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Telesis Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telesis Bio pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

Telesis Bio quarterly revenues are $1.6M, which are larger than Intelligent Bio Solutions quarterly revenues of $872.3K. Telesis Bio's net income of -$12.6M is lower than Intelligent Bio Solutions's net income of -$2.7M. Notably, Telesis Bio's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telesis Bio is 0.04x versus 0.67x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -811.94% compared to Telesis Bio's net margin of -59.9%. Telesis Bio's return on equity of -151.32% beat Standard BioTools's return on equity of -48.03%.

Telesis Bio has a consensus price target of --, signalling upside risk potential of 16171.17%. On the other hand Standard BioTools has an analysts' consensus of -- which suggests that it could grow by 62.28%. Given that Telesis Bio has higher upside potential than Standard BioTools, analysts believe Telesis Bio is more attractive than Standard BioTools.

Telesis Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.606, suggesting its more volatile than the S&P 500 by 60.617%.

Telesis Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telesis Bio pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

Telesis Bio quarterly revenues are $1.6M, which are smaller than Standard BioTools quarterly revenues of $45M. Telesis Bio's net income of -$12.6M is higher than Standard BioTools's net income of -$26.9M. Notably, Telesis Bio's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telesis Bio is 0.04x versus 3.41x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of -811.94% compared to Telesis Bio's net margin of -11.09%. Telesis Bio's return on equity of -151.32% beat LENSAR's return on equity of -56.16%.

Telesis Bio has a consensus price target of --, signalling upside risk potential of 16171.17%. On the other hand LENSAR has an analysts' consensus of -- which suggests that it could grow by 31.42%. Given that Telesis Bio has higher upside potential than LENSAR, analysts believe Telesis Bio is more attractive than LENSAR.

Telesis Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Telesis Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telesis Bio pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

Telesis Bio quarterly revenues are $1.6M, which are smaller than LENSAR quarterly revenues of $13.5M. Telesis Bio's net income of -$12.6M is lower than LENSAR's net income of -$1.5M. Notably, Telesis Bio's price-to-earnings ratio is -- while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telesis Bio is 0.04x versus 1.96x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.

Zomedica has a net margin of -811.94% compared to Telesis Bio's net margin of -95.71%. Telesis Bio's return on equity of -151.32% beat Zomedica's return on equity of -27.17%.

Telesis Bio has a consensus price target of --, signalling upside risk potential of 16171.17%. On the other hand Zomedica has an analysts' consensus of -- which suggests that it could grow by 106.44%. Given that Telesis Bio has higher upside potential than Zomedica, analysts believe Telesis Bio is more attractive than Zomedica.

Telesis Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zomedica has a beta of 1.044, suggesting its more volatile than the S&P 500 by 4.385%.

Telesis Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zomedica offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telesis Bio pays -- of its earnings as a dividend. Zomedica pays out -- of its earnings as a dividend.

Telesis Bio quarterly revenues are $1.6M, which are smaller than Zomedica quarterly revenues of $7M. Telesis Bio's net income of -$12.6M is lower than Zomedica's net income of -$6.7M. Notably, Telesis Bio's price-to-earnings ratio is -- while Zomedica's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telesis Bio is 0.04x versus 4.44x for Zomedica. Usually stocks with elevated PS ratios are considered overvalued.